JANSSEN PHARMACEUTICALS V. WATSON LABORATORIES , No. 12-1693 (Fed. Cir. 2012)

Annotate this Case

Download PDF

Case: 12-1693 Document: 9 Page: 1 Filed: 10/09/2012 NOTE: This order is nonprecedential. Wntteb ~tate~ ~ourt of §ppeaI~ for tbe jfeberaI (!Circuit JANSSEN PHARMACEUTICALS, INC. AND JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC, Plaintiffs-Appellees, v. WATSON LABORATORIES, INC. AND SANDOZ, INC., Defendants, AND LUPIN PHARMACEUTICALS, INC. LTD., AND LUPIN Defendants-Appellants. 2012-1693 Appeal from the United States District Court for the District of New Jersey in consolidated case no. 08-CV5103, Judge Stanley R. Chesler. ON MOTION ORDER Case: 12-1693 Document: 9 Page: 2 Filed: 10/09/2012 JANSSEN PHARMACEUTICALS V. WATSON LABORATORIES 2 Lupin Pharmaceuticals, Inc. et al. (Lupin) moves to expedite the appeal, briefing, and oral argument. Lupin states that Janssen Pharmaceuticals, Inc. et al. (Janssen) oppose. Upon consideration thereof, IT Is ORDERED THAT: The motions are granted to the following extent: Lupin's opening brief is due no later than October 26, 2012; Janssen's brief is due no later than November 30, 2012; Lupin's reply brief and the joint appendix are due no later than December 10, 2012. No extensions of time should be anticipated. Oral argument will be scheduled by subsequent order. FOR THE COURT /s/ Jan Horbaly Jan Horbaly Clerk s8

Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.